Drug Type Biosimilar, Monoclonal antibody |
Synonyms Nivolumab Biosimilar (Bioviz Technologies Pvt Ltd.), 纳武利尤单抗生物类似药(Bioviz Technologies Pvt Ltd.) |
Target |
Action inhibitors |
Mechanism PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | India | 01 Jan 2025 |






